Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
LEGEND BIOTECH CORP (LEGN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$22.54-1.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.59 → 0.54 EPS · FY ending Dec 31, 2027 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for LEGN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
CARVYKTI sales growth | Legend Biotech is nearing profitability with growing sales of CARVYKTI. | Intact | revenue falls below $1.4B in FY27 | Revenue: $387.5M FY2026-Q2; GAAP. Published target: >= $1.8B revenue in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 2026387,500,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk Healthcare investment with a cyclical exposure, not a clearly established durable compounder from the evidence available. The thesis state is insufficient because there is not enough recent financial-performance history to assess the business trend.
The snapshot provides no valuation level or market-expectations evidence, so it is not possible to judge whether LEGN is cheap, fair, or expensive versus peers. No pricing fragility signals fired, but that does not establish what the market already assumes.
The Healthcare sector backdrop has improved, rising from 7.6 to 18.0, which may support the sector near term. Company-specific fundamentals remain hard to assess, and the next report carries elevated risk: the estimated miss probability is 45%, with recent peer misses noted.
Near term, a weakening jobs trend could increase recession concerns and pressure cyclical Healthcare names, while continued earnings strength and higher guidance from VRTX, REGN, and MRNA could sustain sector momentum. Misses or lower guidance from those bellwethers could weaken that support; the snapshot offers little direct evidence about LEGN’s own multi-year execution.
The 1-3 year view is uncertain: sector conditions have improved, but elevated risk and limited company-specific financial evidence leave the long-term thesis unconfirmed. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| New data shows strong potential for CARVYKTI to treat cancer. |
| Improving |
| adoption trends weaken or new data disappoints |
Qualitative: Positive data & adoption Q2 2026 earnings beat, first profitable quarter, and strong Carvykti sales reinforce positive adoption and data trends. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Adjusted profitability near term | A primary condition in LEGEND BIOTECH CORP's published investment case. The stated target is adjusted profit near break-even in FY26. | Intact | profitability delayed beyond FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.81 → $0.54 · observed estimates
$1.78B → $1.75B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.81 | $1,775,081,608 | 5 / 10 |
| 2026-07-25 | $0.81 | $1,775,081,608 | 5 / 10 |
| 2026-07-26 | $0.80 | $1,779,373,937 | 5 / 10 |
| 2026-07-27 | $0.80 | $1,779,373,937 | 5 / 10 |
| 2026-07-28 | $1.21 | $1,818,295,890 | 5 / 11 |
| 2026-07-29 | $1.21 | $1,811,306,250 | 5 / 11 |
| 2026-07-30 | $1.21 | $1,811,306,250 | 5 / 11 |
| 2026-07-31 | $1.21 | $1,811,306,250 | 5 / 11 |
| 2026-08-01 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-02 | $1.21 | $1,811,306,250 | 5 / 11 |
| 2026-08-03 | $1.21 | $1,811,306,250 | 5 / 11 |
| 2026-08-04 | $1.21 | $1,811,306,250 | 5 / 11 |
| 2026-08-05 | $1.21 | $1,811,306,250 | 5 / 11 |
| 2026-08-06 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-07 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-08 | $1.21 | $1,811,306,250 | 5 / 11 |
| 2026-08-09 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-10 | $1.21 | $1,811,306,250 | 5 / 11 |
| 2026-08-12 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-13 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-14 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-15 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-16 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-17 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-18 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-19 | $0.78 | $1,773,904,008 | 5 / 9 |
| 2026-08-20 | $0.62 | $1,771,687,274 | 4 / 9 |
| 2026-08-21 | $0.62 | $1,771,687,274 | 4 / 9 |
| 2026-08-22 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-08-23 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-08-24 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-08-25 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-08-26 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-08-27 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-08-28 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-08-29 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-08-30 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-08-31 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-01 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-02 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-03 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-04 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-05 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-06 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-07 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-08 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-09 | $0.62 | $1,771,687,274 | 4 / 10 |
| 2026-09-10 | $0.62 | $1,771,688,489 | 4 / 10 |
| 2026-09-11 | $0.62 | $1,771,688,489 | 4 / 9 |
| 2026-09-12 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-13 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-14 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-15 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-16 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-17 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-18 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-19 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-20 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-21 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-22 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-23 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-24 | $0.60 | $1,771,688,489 | 4 / 9 |
| 2026-09-25 | $0.60 | $1,771,688,489 | 3 / 8 |
| 2026-09-26 | $0.60 | $1,771,688,489 | 3 / 8 |
| 2026-09-27 | $0.60 | $1,771,688,489 | 3 / 8 |
| 2026-09-28 | $0.60 | $1,771,688,489 | 3 / 8 |
| 2026-09-29 | $0.60 | $1,771,688,489 | 3 / 8 |
| 2026-09-30 | $0.60 | $1,771,688,489 | 3 / 8 |
| 2026-10-01 | $0.59 | $1,762,256,203 | 3 / 8 |
| 2026-10-02 | $0.59 | $1,762,256,203 | 3 / 8 |
| 2026-10-03 | $0.59 | $1,762,256,203 | 3 / 8 |
| 2026-10-04 | $0.59 | $1,762,256,203 | 3 / 8 |
| 2026-10-05 | $0.59 | $1,762,256,203 | 3 / 8 |
| 2026-10-06 | $0.59 | $1,762,256,203 | 3 / 8 |
| 2026-10-07 | $0.58 | $1,757,756,203 | 3 / 8 |
| 2026-10-08 | $0.58 | $1,757,756,203 | 3 / 8 |
| 2026-10-09 | $0.58 | $1,755,468,346 | 3 / 8 |
| 2026-10-10 | $0.58 | $1,755,468,346 | 3 / 8 |
| 2026-10-11 | $0.56 | $1,754,124,078 | 3 / 8 |
| 2026-10-12 | $0.56 | $1,754,124,078 | 3 / 8 |
| 2026-10-13 | $0.56 | $1,754,124,078 | 3 / 8 |
| 2026-10-14 | $0.54 | $1,743,106,935 | 3 / 8 |
| 2026-10-15 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-16 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-17 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-18 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-19 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-20 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-21 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-22 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-23 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-24 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-25 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-26 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-27 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-28 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-29 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-30 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-10-31 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-11-01 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-11-02 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-11-03 | $0.54 | $1,745,031,221 | 3 / 8 |
| 2026-11-04 | $0.54 | $1,745,031,221 | 3 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.